ADAM8 as a drug target in pancreatic cancer

Nature Communications

Volumn 6, Issue , 2015, Pages

  Schlomann, Uwe ^a,b   Koller, Garrit ^a   Conrad, Catharina ^b   Ferdous, Taheera ^a   Golfi, Panagiota ^a   Garcia, Adolfo Molejon ^a   Höfling, Sabrina ^a   Parsons, Maddy ^a   Costa, Patricia ^c   Soper, Robin ^c   Bossard, Maud ^c   Hagemann, Thorsten ^c   Roshani, Rozita ^c   Sewald, Norbert ^d   Ketchem, Randal R ^e   Moss, Marcia L ^f   Rasmussen, Fred H ^f   Miller, Miles A ^g   Lauffenburger, Douglas A ^g   Tuveson, David A ^h   Nimsky, Christopher ^b   Bartsch, Jörg W ^a,b   more..

^a KING'S COLLEGE LONDON   (United Kingdom)

^b PHILIPPS UNIVERSITY MARBURG   (Germany)

^c QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^d BIELEFELD UNIVERSITY   (Germany)

^e AMGEN INC   (United States)

^f BioZyme Inc   (United States)

^g Massachusetts Institute of Technology Cambridge   (United States)

^h Howard Hughes Medical Institute Cold Spring Harbor Laboratory Cold Spring Harbor   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADAM PROTEIN; ADAM10 ENDOPEPTIDASE; ADAM12 PROTEIN; ADAM17 PROTEIN; ADAM8 PROTEIN; ADAM9 PROTEIN; BETA1 INTEGRIN; BK 1361; CD23 ANTIGEN; COLLAGEN TYPE 1; COLLAGEN TYPE 4; CYCLOPEPTIDE; FIBRONECTIN; GELATINASE A; GELATINASE B; MATRIX METALLOPROTEINASE 14; METALLOPROTEINASE INHIBITOR; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; UNCLASSIFIED DRUG; ADAM8 PROTEIN, HUMAN; FOCAL ADHESION KINASE; HYDROXAMIC ACID; MEMBRANE PROTEIN; PROTEIN BINDING;

CANCER; CELLS AND CELL COMPONENTS; DRUG; GENE EXPRESSION; GENETIC ANALYSIS; PROTEIN; RODENT; TUMOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL INVASION; CELL MIGRATION; CELLULAR DISTRIBUTION; COMPLEX FORMATION; CONTROLLED STUDY; DRUG TARGETING; ENZYME INHIBITION; FEMALE; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IC50; IN VITRO STUDY; INTRACELLULAR SIGNALING; MALE; MOUSE; NONHUMAN; PANCREAS ADENOCARCINOMA; PROTEIN DOMAIN; PROTEIN MOTIF; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; REPEATED DRUG DOSE; TUMOR GROWTH; ANIMAL; ANTAGONISTS AND INHIBITORS; CELL MOTION; DRUG EFFECTS; ENZYMOLOGY; EXTRACELLULAR SPACE; GENE SILENCING; KAPLAN MEIER METHOD; METABOLISM; MOLECULARLY TARGETED THERAPY; PANCREAS CARCINOMA; PANCREATIC NEOPLASMS; PATHOLOGY; PHOSPHORYLATION; PROTEIN MULTIMERIZATION; PROTEIN PROCESSING; SIGNAL TRANSDUCTION; TUMOR CELL LINE; TUMOR INVASION; WESTERN BLOTTING;

MUS;

ADAM PROTEINS; ANIMALS; ANTIGENS, CD29; BLOTTING, WESTERN; CARCINOMA, PANCREATIC DUCTAL; CELL LINE, TUMOR; CELL MOVEMENT; EXTRACELLULAR SPACE; FOCAL ADHESION PROTEIN-TYROSINE KINASES; GENE KNOCKDOWN TECHNIQUES; HUMANS; HYDROXAMIC ACIDS; KAPLAN-MEIER ESTIMATE; MATRIX METALLOPROTEINASE 14; MATRIX METALLOPROTEINASE 2; MEMBRANE PROTEINS; MICE; MOLECULAR TARGETED THERAPY; NEOPLASM INVASIVENESS; PANCREATIC NEOPLASMS; PEPTIDES, CYCLIC; PHOSPHORYLATION; PROTEIN BINDING; PROTEIN MULTIMERIZATION; PROTEIN PROCESSING, POST-TRANSLATIONAL; SIGNAL TRANSDUCTION;

EID: 84944925203     PISSN: None     EISSN: 20411723     Source Type: Journal    
DOI: 10.1038/ncomms7175     Document Type: Article

References (60)

1. Erkan, M. et al. The role of stroma in pancreatic cancer: diagnostic and therapeutic implications. Nat. Rev. Gastroenterol. Hepatol. 9, 454-467 (2012).
2. Hingorani, S. R. et al. Preinvasive and invasive ductal pancreatic cancer and its early detection in the mouse. Cancer Cell 4, 437-450 (2003).
3. Hezel, A. F., Kimmelman, A. C., Stanger, B. Z., Bardeesy, N. & Depinho, R. A. Genetics and biology of pancreatic ductal adenocarcinoma. Genes Dev. 20, 1218-1249 (2006).
4. Tuveson, D. A. & Neoptolemos, J. P. Understanding metastasis in pancreatic cancer: a call for new clinical approaches. Cell 148, 21-23 (2012).
5. Haeno, H. et al. Computational modeling of pancreatic cancer reveals kinetics of metastasis suggesting optimum treatment strategies. Cell 148, 362-375 (2012).
6. Rhim, A. D. et al. EMT and dissemination precede pancreatic tumor formation. Cell 148, 349-361 (2012).
7. Kong, X., Li, L., Li, Z. & Xie, K. Targeted destruction of the orchestration of the pancreatic stroma and tumor cells in pancreatic cancer cases: molecular basis for therapeutic implications. Cytokine Growth Factor Rev. 23, 343-356 (2012).
8. Shields, M. A., Dangi-Garimella, S., Redig, A. J. & Munshi, H. G. Biochemical role of the collagen-rich tumour microenvironment in pancreatic cancer progression. Biochem. J. 441, 541-552 (2012).
9. Murphy, G. The ADAMs: signalling scissors in the tumour microenvironment. Nat. Rev. Cancer 8, 929-941 (2008).
10. Hanahan, D. & Coussens, L. M. Accessories to the crime: functions of cells recruited to the tumor microenvironment. Cancer Cell 21, 309-322 (2012).
11. Mochizuki, S. & Okada, Y. ADAMs in cancer cell proliferation and progression. Cancer Sci. 98, 621-628 (2007).
12. Zack, M. D. et al. ADAM-8 isolated from human osteoarthritic chondrocytes cleaves fibronectin at Ala(271). Arthritis Rheum. 60, 2704-2713 (2009).
13. Moss, M. L. & Bartsch, J. W. Therapeutic benefits from targeting of ADAM family members. Biochemistry 43, 7227-7235 (2004).
14. Blobel, C. P. ADAMs: key components in EGFR signalling and development. Nat. Rev. Mol. Cell Biol. 6, 32-43 (2005).
15. Valkovskaya, N. et al. ADAM8 expression is associated with increased invasiveness and reduced patient survival in pancreatic cancer. J. Cell. Mol. Med. 11, 1162-1174 (2007).
16. Yoshida, S., Setoguchi, M., Higuchi, Y., Akizuki, S. & Yamamoto, S. Molecular cloning of cDNA encoding MS2 antigen, a novel cell surface antigen strongly expressed in murine monocytic lineage. Int. Immunol. 2, 585-591 (1990).
17. Yoshiyama, K., Higuchi, Y., Kataoka, M., Matsuura, K. & Yamamoto, S. CD156 (human ADAM8): expression, primary amino acid sequence, and gene location. Genomics 41, 56-62 (1997).
18. Schlomann, U., Rathke-Hartlieb, S., Yamamoto, S., Jockusch, H. &Bartsch, J. W. Tumor necrosis factor alpha induces a metalloprotease-disintegrin, ADAM8 (CD 156): implications for neuron-glia interactions during neurodegeneration. J. Neurosci. 20, 7964-7971 (2000).
19. Koller, G. et al. ADAM8/MS2/CD156, an emerging drug target in the treatment of inflammatory and invasive pathologies. Curr. Pharm. Des. 15, 2272-2281 (2009).
20. Wildeboer, D., Naus, S., Amy Sang, Q. X., Bartsch, J. W. & Pagenstecher, A. Metalloproteinase disintegrins ADAM8 and ADAM19 are highly regulated in human primary brain tumors and their expression levels and activities are associated with invasiveness. J. Neuropathol. Exp. Neurol. 65, 516-527 (2006).
21. Ishikawa, N. et al. ADAM8 as a novel serological and histochemical marker for lung cancer. Clin. Cancer Res. 10, 8363-8370 (2004).
22. Fritzsche, F. R. et al. ADAM8 expression in prostate cancer is associated with parameters of unfavorable prognosis. Virchows Arch. 449, 628-636 (2006).
23. Zielinski, V. et al. ADAM8 in squamous cell carcinoma of the head and neck: a retrospective study. BMC Cancer 12, 76 (2012).
24. Zhang, R., Yuan, Y., Zuo, J. & Liu, W. Prognostic and clinical implication of a disintegrin and metalloprotease 8 expression in pediatric medulloblastoma. J. Neurol. Sci. 323, 46-51 (2012).
25. Li, Z. et al. Upregulation of a disintegrin and metalloprotease 8 influences tumor metastasis and prognosis in patients with osteosarcoma. Pathol. Oncol. Res. 18, 657-661 (2012).
26. Romagnoli, M. et al. ADAM8 expression in invasive breast cancer promotes tumor dissemination and metastasis. EMBO Mol. Med. 6, 278-294 (2014).
27. Kelly, K. et al. Metalloprotease-disintegrin ADAM8: expression analysis and targeted deletion in mice. Dev. Dyn. 232, 221-231 (2005).
28. Bartsch, J. W. et al. Tumor necrosis factor-alpha (TNF-alpha) regulates shedding of TNF-alpha receptor 1 by the metalloprotease-disintegrin ADAM8: evidence for a protease-regulated feedback loop in neuroprotection. J. Neurosci. 30, 12210-12218 (2010).
29. Gómez-Gaviro, M. et al. Expression and regulation of the metalloproteinase ADAM-8 during human neutrophil pathophysiological activation and its catalytic activity on L-selectin shedding. J. Immunol. 178, 8053-8063 (2007).
30. Fourie, A. M., Coles, F., Moreno, V. & Karlsson, L. Catalytic activity of ADAM8, ADAM15, and MDC-L (ADAM28) on synthetic peptide substrates and in ectodomain cleavage of CD23. J. Biol. Chem. 278, 30469-30477 (2003).
31. Naus, S. et al. Identification of candidate substrates for ectodomain shedding by the metalloprotease-disintegrin ADAM8. Biol. Chem. 387, 337-346 (2006).
32. Naus, S. et al. Ectodomain shedding of the neural recognition molecule CHL1 by the metalloprotease-disintegrin ADAM8 promotes neurite outgrowth and suppresses neuronal cell death. J. Biol. Chem. 279, 16083-16090 (2004).
33. Guaiquil, V. H. et al. ADAM8 is a negative regulator of retinal neovascularization and of the growth of heterotopically injected tumor cells in mice. J. Mol. Med. (Berl) 88, 497-505 (2010).
34. Hernández, I., Moreno, J. L., Zandueta, C., Montuenga, L. & Lecanda, F. Novel alternatively spliced ADAM8 isoforms contribute to the aggressive bone metastatic phenotype of lung cancer. Oncogene 29, 3758-3769 (2010).
35. Schlomann, U. et al. The metalloprotease disintegrin ADAM8. Processing by autocatalysis is required for proteolytic activity and cell adhesion. J. Biol. Chem. 277, 48210-48219 (2002).
36. Eto, K. et al. Functional classification of ADAMs based on a conserved motif for binding to integrin alpha 9beta 1: implications for sperm-egg binding and other cell interactions. J. Biol. Chem. 277, 17804-17810 (2002).
37. Zhang, X. P., Kamata, T., Yokoyama, K., Puzon-McLaughlin, W. & Takada, Y. Specific interaction of the recombinant disintegrin-like domain of MDC-15 (metargidin, ADAM-15) with integrin alphavbeta3. J. Biol. Chem. 273, 7345-7350 (1998).
38. Zigrino, P. et al. Role of ADAM-9 disintegrin-cysteine-rich domains in human keratinocyte migration. J. Biol. Chem. 282, 30785-30793 (2007).
39. Rao, H. et al. Alpha9beta1: a novel osteoclast integrin that regulates osteoclast formation and function. J. Bone Miner. Res. 21, 1657-1665 (2006).
40. Janes, P. W. et al. Adam meets Eph: an ADAM substrate recognition module acts as a molecular switch for ephrin cleavage in trans. Cell 123, 291-304 (2005).
41. Miller, M. A. et al. Proteolytic Activity Matrix Analysis (PrAMA) for simultaneous determination of multiple protease activities. Integr. Biol. (Camb) 3, 422-438 (2011).
42. Lewis, J. M. & Schwartz, M. A. Mapping in vivo associations of cytoplasmic proteins with integrin beta 1 cytoplasmic domain mutants. Mol. Biol. Cell. 6, 151-160 (1995).
43. Ardito, C. M. et al. EGF receptor is required for KRAS-induced pancreatic tumorigenesis. Cancer Cell 22, 304-317 (2012).
44. Navas, C. et al. EGF receptor signalling is essential for k-ras oncogene-driven pancreatic ductal adenocarcinoma. Cancer Cell 22, 318-330 (2012).
45. Botta, G. P., Reginato, M. J., Reichert, M., Rustgi, A. K. & Lelkes, P. I. Constitutive K-RasG12D activation of ERK2 specifically regulates 3D invasion of human pancreatic cancer cells via MMP-1. Mol. Cancer Res. 10, 183-196 (2012).
46. Seton-Rogers, S. Tumorigenesis: pushing pancreatic cancer to take off. Nat. Rev. Cancer 12, 739 (2012).
47. Grzesiak, J. J. et al. Knockdown of the β(1) integrin subunit reduces primary tumor growth and inhibits pancreatic cancer metastasis. Int. J. Cancer 129, 2905-2915 (2011).
48. Layton, T., Stalens, C., Gunderson, F., Goodison, S. & Silletti, S. Syk tyrosine kinase acts as a pancreatic adenocarcinoma tumor suppressor by regulating cellular growth and invasion. Am. J. Pathol. 175, 2625-2636 (2009).
49. Grippo, P. J. et al. Concurrent PEDF deficiency and Kras mutation induce invasive pancreatic cancer and adipose-rich stroma in mice. Gut 61, 1454-1464 (2012).
50. Lu, G. et al. Selection of peptide inhibitor to matrix metalloproteinase-2 using phage display and its effects on pancreatic cancer cell lines PANC-1 and CFPAC-1. Int. J. Biol. Sci. 8, 650-662 (2012).
51. Segarra, M. et al. Dual function of focal adhesion kinase in regulating integrin-induced MMP-2 and MMP-9 release by human T lymphoid cells. FASEB J. 19, 1875-1877 (2005).
52. Liu, J. et al. BMP2 induces PANC-1 cell invasion by MMP-2 overexpression through ROS and ERK. Front. Biosci. (Landmark Ed) 17, 2541-2549 (2012).
53. Stanton, H. et al. The activation of ProMMP-2 (gelatinase A) by HT1080 fibrosarcoma cells is promoted by culture on a fibronectin substrate and is concomitant with an increase in processing of MT1-MMP (MMP-14) to a 45 kDa form. J. Cell. Sci. 111, 2789-2798 (1998).
54. Valkovskaya, N. V. Hypoxia-dependent expression of ADAM8 in human pancreatic cancer cell lines. Exp. Oncol. 30, 129-132 (2008).
55. Lorenzen, M., Trad, A. & Grötzinger, J. Multimerisation of A disintegrin and metalloprotease protein-17 (ADAM17) is mediated by its EGF-like domain. Biochem. Biophys. Res. Commun. 415, 330-336 (2011).
56. Stautz, D. et al. Cell-surface metalloprotease ADAM12 is Internalized by a clathrin- and Grb2-dependent mechanism. Traffic 13, 1532-1546 (2012).
57. Takeda, S., Igarashi, T., Mori, H. & Araki, S. Crystal structures of VAP1 reveal ADAMs' MDC domain architecture and its unique C-shaped scaffold. EMBO J. 25, 2388-2396 (2006).
58. Bridges, L. C., Hanson, K. R., Tani, P. H., Mather, T. & Bowditch, R. D. Integrin alpha4beta1-dependent adhesion to ADAM 28 (MDC-L) requires an extended surface of the disintegrin domain. Biochemistry 42, 3734-3741 (2003).
59. Moss, M. L. & Rasmussen, F. H. Fluorescent substrates for the proteinases ADAM17, ADAM10, ADAM8, and ADAM12 useful for high-throughput inhibitor screening. Anal. Biochem. 366, 144-148 (2007).
60. Parsons, M., Messent, A. J., Humphries, J. D., Deakin, N. O. & Humphries, M. J. Quantification of integrin receptor agonism by fluorescence lifetime imaging. J. Cell. Sci. 121, 265-271 (2008).